CBD and Metoprolol: Drug Interaction Overview
What's actually known about combining cannabidiol with the beta-blocker metoprolol, and where the evidence gets thin.
There's a plausible mechanism for CBD to raise metoprolol blood levels — both are processed by the liver enzyme CYP2D6, and CBD inhibits it. But the actual clinical data is thin: mostly in-vitro work, case reports, and extrapolation from how CBD affects other CYP2D6 drugs. If you take metoprolol for blood pressure, arrhythmia, or heart failure, don't freelance with CBD. Tell your cardiologist, check your pulse and BP, and start low if you proceed at all.
Plain-language summary
Metoprolol is a beta-blocker used for high blood pressure, angina, certain arrhythmias, and heart failure. It is mostly broken down in the liver by an enzyme called CYP2D6 [1][2].
CBD (cannabidiol) inhibits CYP2D6 in laboratory studies [3][4]. In theory, that means taking CBD alongside metoprolol could slow the breakdown of metoprolol, raising its blood levels and amplifying its effects — slower heart rate, lower blood pressure, more fatigue or dizziness.
That's the theory. Direct human studies of CBD + metoprolol specifically have not been published as of this writing. Most interaction databases (Drugs.com, Lexicomp) flag the combination as a moderate interaction worth monitoring, based on the shared enzyme pathway rather than dedicated trials [5].
This article is not medical advice. If you take metoprolol, talk to the prescriber before adding CBD in any form.
What probably works (well-supported)
Honestly, very little here is "strong" evidence specific to this pair. What is well-supported is the underlying biology:
- Metoprolol is metabolized primarily by CYP2D6. This is established pharmacology; people who are genetically poor CYP2D6 metabolizers already have higher metoprolol exposure and more side effects Strong evidence [1][2].
- CBD inhibits CYP2D6 in vitro at clinically achievable concentrations. Multiple lab studies have shown this Strong evidence [3][4].
- CBD raises blood levels of at least some other CYP2D6 substrates in humans (the clearest case is clobazam's active metabolite N-desmethylclobazam, though that involves multiple enzymes) Strong evidence [6].
From these three facts together, predicting that CBD can raise metoprolol exposure is reasonable — but it's an inference, not a measured fact in humans.
What might work / weak evidence
- Clinically meaningful CBD-metoprolol interaction in real patients. Plausible based on mechanism, but specific clinical pharmacokinetic studies of this pair have not been published in the major literature Weak / limited [5].
- CBD lowering blood pressure on its own. A small randomized crossover trial in healthy men found a single 600 mg oral CBD dose modestly reduced resting and stress-related blood pressure [7]. If real and durable, that would add to metoprolol's BP-lowering effect. The study was small (n=9), single-dose, and in healthy volunteers — extrapolating to chronic dosing in cardiac patients is speculative Weak / limited.
- Dose-dependence. The CYP inhibition concern scales with CBD dose. Trace CBD in a topical or a 5 mg gummy is mechanistically very different from 600–1500 mg/day used in epilepsy trials Weak / limited [3][8].
What doesn't work / common myths
- "CBD is natural so it can't interact with heart medications." False. Natural compounds interact with drug-metabolizing enzymes all the time — grapefruit juice is the classic example. CBD's interaction profile is well-documented Strong evidence [3][6].
- "Low-dose CBD products are guaranteed safe with metoprolol." Unknown, not guaranteed. The threshold dose at which CBD meaningfully inhibits CYP2D6 in humans isn't precisely mapped No data.
- "CBD will replace my beta-blocker." No clinical evidence supports CBD as a substitute for metoprolol in hypertension, arrhythmia, or heart failure No data.
- "Smoked or vaped cannabis is the same risk profile." Different. Inhaled cannabis acutely raises heart rate via THC, which works against what metoprolol is trying to do — a separate concern from the CBD-CYP2D6 issue Strong evidence [9].
What we don't know
- The actual magnitude of metoprolol AUC/Cmax increase when co-administered with typical consumer CBD doses (10–100 mg) in humans.
- Whether the interaction is clinically significant at low CBD doses or only at epilepsy-trial doses (hundreds of mg/day).
- Whether CBD route of administration (oral, sublingual, inhaled, topical) meaningfully changes the interaction risk.
- Whether genetic CYP2D6 status (poor, intermediate, extensive, ultrarapid metabolizer) modifies the interaction.
- Whether long-term CBD use causes enzyme induction or other adaptive changes that shift the picture.
This is a genuine evidence gap. The shrug is honest.
Comparison with standard cardiology guidance
Standard cardiology practice for someone on metoprolol involves monitoring heart rate and blood pressure, watching for fatigue or lightheadedness, and adjusting the dose as needed. The drug works; metoprolol has decades of trial evidence for hypertension, post-MI care, and heart failure with reduced ejection fraction [2].
There is no recognized clinical role for CBD as cardiac therapy in current major guidelines (ACC/AHA, ESC). CBD has one FDA-approved indication — certain pediatric seizure disorders (Epidiolex) [8]. Everything else, including any cardiovascular use, is off-label and not endorsed by cardiology societies as of this writing.
If a patient wants to use CBD for anxiety, sleep, or pain while taking metoprolol, the reasonable clinical posture is: disclose it, start at the lowest plausible dose, monitor home BP and pulse, and watch for new dizziness, fatigue, bradycardia, or syncope.
Risks and practical cautions
Most plausible adverse effects of the combination:
- Exaggerated bradycardia (slow heart rate)
- Symptomatic hypotension (dizziness, fainting on standing)
- Increased fatigue or exercise intolerance
- In susceptible patients (heart failure, conduction disease), risk of more serious events
Higher-risk situations:
- Elderly patients
- Anyone with baseline low heart rate (<60), AV block, or heart failure
- High-dose CBD use (e.g., Epidiolex-range, several hundred mg/day)
- Poor CYP2D6 metabolizers (genetic testing not routinely done)
- Concomitant other CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, etc.)
Practical steps if you and your prescriber decide to proceed:
- Tell your cardiologist or primary care provider. Don't hide it.
- Use a CBD product with a current third-party Certificate of Analysis Certificate of Analysis.
- Start at a low CBD dose.
- Check home blood pressure and pulse daily for the first 1–2 weeks.
- Stop and call your provider if you get unusual fatigue, dizziness on standing, fainting, or a resting pulse persistently below the range your cardiologist set.
This article is informational, not medical advice. Do not start, stop, or change metoprolol or CBD based on what you read here. Talk to a licensed clinician who knows your full history.
Sources
- Peer-reviewed Blake CM, Kharasch ED, Schwab M, Nagele P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clinical Pharmacology & Therapeutics. 2013;94(3):394-399.
- Government U.S. Food and Drug Administration. Lopressor (metoprolol tartrate) prescribing information.
- Peer-reviewed Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metabolism and Disposition. 2011;39(11):2049-2056.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Reported Drugs.com Interaction Checker. Cannabidiol and metoprolol drug interaction summary.
- Peer-reviewed Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246-1251.
- Peer-reviewed Jadoon KA, Tan GD, O'Sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2017;2(12):e93760.
- Government U.S. Food and Drug Administration. Epidiolex (cannabidiol) prescribing information.
- Peer-reviewed Jouanjus E, Lapeyre-Mestre M, Micallef J; French Association of the Regional Abuse and Dependence Monitoring Centres. Cannabis use: signal of increasing risk of serious cardiovascular disorders. Journal of the American Heart Association. 2014;3(2):e000638.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.